Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy

Supportive Care in Cancer

Volumn 23, Issue 3, 2015, Pages 687-694

  Jung, Hee Won ^a   Kim, Jin Won ^a   Kim, Ji Yeon ^a   Kim, Sun Wook ^a   Yang, Hyun Kyung ^a   Lee, Joon Woo ^a   Lee, Keun Wook ^a   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Kim, Kwang Il ^a   Kim, Cheol Ho ^a   Kim, Jee Hyun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Colon cancer; Mortality; Sarcopenia; Toxicity

Indexed keywords

ADVERSE DRUG REACTION; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; DRUG ADMINISTRATION; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; OXALIPLATIN; PLATINUM COMPLEX; SERUM ALBUMIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVERSE EFFECTS; AGED; ANEMIA; ARTICLE; ASTHENIA; BODY COMPOSITION; BODY MASS; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; COLON CANCER; COLONIC NEOPLASMS; COMPLICATION; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG THERAPY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; LIVER DYSFUNCTION; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUCOSA INFLAMMATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; MUSCLE MASS; NAUSEA; NEUROPATHY; NEUTROPENIA; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PSOAS MUSCLE; SARCOPENIA; SKELETAL MUSCLE; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; VERY ELDERLY; VOMITING;

ADMINISTRATION AND DOSAGE; ADULT; ADVERSE EFFECTS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMPLICATIONS; DRUG THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUSCLE, SKELETAL; OBESITY; ORGANOPLATINUM COMPOUNDS; PHYSIOLOGY; PHYSIOPATHOLOGY; SARCOPENIA;

EID: 84963939906     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2418-6     Document Type: Article

References (45)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19(8):1893–1907. doi:10.1158/1055-9965.epi-10-0437
2. Kim Y, Jun JK, Choi KS, Lee HY, Park EC (2011) Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev: APJCP 12(3):725–730
3. Cesari M, Leeuwenburgh C, Lauretani F, Onder G, Bandinelli S, Maraldi C, Guralnik JM, Pahor M, Ferrucci L (2006) Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin nutri 83(5):1142–1148
4. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K (2013) Frailty in elderly people. Lancet 381(9868):752–762. doi:10.1016/S0140-6736(12)62167-9
5. Jung HW, Kim SW, Ahn S, Lim JY, Han JW, Kim TH, Kim KW, Kim KI, Kim CH (2014) Prevalence and outcomes of frailty in Korean elderly population: comparisons of a multidimensional frailty index with two phenotype models. PLoS One 9(2):e87958. doi:10.1371/journal.pone.0087958
6. Kim SW, Han HS, Jung HW, Kim KI, Hwang DW, Kang SB, Kim CH (2014) Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA surg 149(7):633–640. doi:10.1001/jamasurg.2014.241
7. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A: Biol Med Sci 56(3):M146–156
8. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP (2010) Understanding sarcopenia as a geriatric syndrome. Curr opin clin nutri metabol care 13(1):1–7. doi:10.1097/MCO.0b013e328333c1c1
9. Schaap LA, Pluijm SM, Deeg DJ, Visser M (2006) Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 119(6):526 e529–517. doi:10.1016/j.amjmed.2005.10.049
10. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, Colbert LH, Pahor M, Rubin SM, Tylavsky FA, Visser M (2009) Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A: Biol Med Sci 64(11):1183–1189. doi:10.1093/gerona/glp097
11. Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G (2012) Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 31(5):652–658. doi:10.1016/j.clnu.2012.02.007
12. Abellan van Kan G (2009) Epidemiology and consequences of sarcopenia. J Nutri, Health & Aging 13(8):708–712
13. Janssen I (2006) Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 54(1):56–62. doi:10.1111/j.1532-5415.2005.00540.x
14. Jung HW, Kim SW, Chin HJ, Kim KI, Kim CH (2013) Skeletal muscle mass as a predictor of mortality in the elderly population. J Kor Med Assoc 85(2):167–173
15. Hasselager R, Gogenur I (2014) Core muscle size assessed by perioperative abdominal CT scan is related to mortality, postoperative complications, and hospitalization after major abdominal surgery: a systematic review. Langenbecks Archives surg 399(3):287–295. doi:10.1007/s00423-014-1174-x
16. Lee JS, He K, Harbaugh CM, Schaubel DE, Sonnenday CJ, Wang SC, Englesbe MJ, Eliason JL (2011) Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. J Vasc Surg 53(4):912–917. doi:10.1016/j.jvs.2010.10.111
17. Sheetz KH, Zhao L, Holcombe SA, Wang SC, Reddy RM, Lin J, Orringer MB, Chang AC (2013) Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer. Dis Esophagus 26(7):716–722. doi:10.1111/dote.12020
18. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, Holcombe SA, Wang SC, Segev DL, Sonnenday CJ (2010) Sarcopenia and mortality after liver transplantation. J Am Coll Surg 211(2):271–278. doi:10.1016/j.jamcollsurg.2010.03.039
19. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920–2926. doi:10.1158/1078-0432.CCR-08-2242
20. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM (2013) Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 17(12):2123–2132. doi:10.1007/s11605-013-2348-5
21. Sinicrope FA, Foster NR, Sargent DJ, O’Connell MJ, Rankin C (2010) Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res 16(6):1884–1893. doi:10.1158/1078-0432.CCR-09-2636
22. Greene FL, American Joint Committee on Cancer, American Cancer Society (2002) AJCC cancer staging manual, 6th edn. Springer, New York
23. Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH (2013) Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. Jpn J Clin Oncol 43(2):132–138. doi:10.1093/jjco/hys195
24. Hoshikawa Y, Iida T, Ii N, Muramatsu M, Nakajima Y, Chumank K, Kanehisa H (2012) Cross-sectional area of psoas major muscle and hip flexion strength in youth soccer players. Eur J Appl Physiol 112(10):3487–3494. doi:10.1007/s00421-012-2335-7
25. Han SS, Kim KW, Kim KI, Na KY, Chae DW, Kim S, Chin HJ (2010) Lean mass index: a better predictor of mortality than body mass index in elderly Asians. J Am Geriatr Soc 58(2):312–317. doi:10.1111/j.1532-5415.2009.02672.x
26. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257. doi:10.1056/NEJMoa022289
27. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Archives pathol lab med 124(7):979–994. doi:10.1043/0003-9985(2000)124<0979:PFICC>2.0.CO;2
28. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J chron dis 40(5):373–383
30. Hryniuk WM, Figueredo A, Goodyear M (1987) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14(4 Suppl 4):3–11
31. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. doi:10.1056/NEJMoa032709
32. National Cancer Institute (U.S.) (2009) Common terminology criteria for adverse events (CTCAE). NIH publication, vol no 10–5410, Rev. edn. U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, Md.
33. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539–1547. doi:10.1200/JCO.2012.45.2722
34. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. lancet oncol 9(7):629–635. doi:10.1016/S1470-2045(08)70153-0
35. Cousin S, Hollebecque A, Koscielny S, Mir O, Varga A, Baracos VE, Soria JC, Antoun S (2014) Low skeletal muscle is associated with toxicity in patients included in phase I trials. Investig New Drugs 32(2):382–387. doi:10.1007/s10637-013-0053-6
36. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13(11):3264–3268. doi:10.1158/1078-0432.ccr-06-3067
37. Larsson SC, Rutegard J, Bergkvist L, Wolk A (2006) Physical activity, obesity, and risk of colon and rectal cancer in a cohort of Swedish men. Eur J Cancer 42(15):2590–2597. doi:10.1016/j.ejca.2006.04.015
38. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H (2013) Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One 8(1):e53916. doi:10.1371/journal.pone.0053916
39. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, DeGramont A, O’Connell MJ, Sargent DJ, Adjuvant Colon Canc E (2013) Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer 119(8):1528–1536. doi:10.1002/cncr.27938
40. Kim JW, Kim YJ, Lee KW, Chang H, Lee JO, Kim KI, Bang SM, Lee JS, Kim CH, Kim JH (2014) The early discontinuation of palliative chemotherapy in older patients with cancer. Support Care Cancer 22(3):773–781. doi:10.1007/s00520-013-2033-y
41. Peltonen JE, Taimela S, Erkintalo M, Salminen JJ, Oksanen A, Kujala UM (1998) Back extensor and psoas muscle cross-sectional area, prior physical training, and trunk muscle strength—a longitudinal study in adolescent girls. Eur J Appl Physiol Occup Physiol 77(1–2):66–71
42. Antoun S, Borget I, Lanoy E (2013) Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Sup Palliat Care 7(4):383–389. doi:10.1097/spc.0000000000000011
43. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39(4):412–423. doi:10.1093/ageing/afq034
44. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H (2014) Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Direc Assoc 15(2):95–101. doi:10.1016/j.jamda.2013.11.025
45. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A: Biol Med Sci 69(5):547–558. doi:10.1093/gerona/glu010